UPDATE 2-J&J arthritis drug sirukumab raises safety concerns -FDA staff
July 31, 2017 at 09:19 AM EDT
July 31 (Reuters) - There were more deaths in patients taking Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.
